<div id="readability-page-1"><p>In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on MiMedx Group, with a price target of <span id="expert-recommendation-target">$12.00</span>.</p><h3>Claim 70% Off TipRanks This Holiday Season</h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, Indivior, and Alvotech. According to TipRanks, Byrnes has an average return of <span>-4.3%</span> and a 37.17% success rate on recommended stocks. </p> <p>In a report released on December 17, Mizuho Securities also maintained a Buy rating on the stock with a $10.00 price target.</p></div>

MDXG

<p>Northland Securities' Carl Byrnes maintains a Buy rating on MiMedx Group with a $12.00 price target. Mizuho Securities also maintains a Buy rating with a $10.00 target. Byrnes, focusing on healthcare stocks, has an average return of -4.3% and a 37.17% success rate according to TipRanks.</p>

Northland Securities Remains a Buy on MiMedx Group (MDXG)